User contributions for Rithish Nimmagadda

17 May 2024

• 16:5816:58, 17 May 2024 diff hist +15‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 16:4016:40, 17 May 2024 diff hist +2,182‎ N Lotilaner ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety..." current
• 15:4015:40, 17 May 2024 diff hist +17‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 15:3815:38, 17 May 2024 diff hist +7,057‎ Bimekizumab ‎No edit summary current

11 May 2024

• 22:3822:38, 11 May 2024 diff hist 0‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 22:3422:34, 11 May 2024 diff hist +22‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 22:3222:32, 11 May 2024 diff hist +13‎ Mirikizumab-mrkz ‎No edit summary current
• 22:3122:31, 11 May 2024 diff hist 0‎ Mirikizumab-mrkz ‎No edit summary
• 22:2622:26, 11 May 2024 diff hist +5,235‎ Mirikizumab-mrkz ‎No edit summary
• 20:4820:48, 11 May 2024 diff hist −2‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 20:4820:48, 11 May 2024 diff hist +16‎ User:Rithish Nimmagadda ‎ →‎Pages Authored/Co-authored/Collaborated
• 20:2120:21, 11 May 2024 diff hist +3,351‎ N Elfabrio ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio..." current
• 19:3619:36, 11 May 2024 diff hist +44‎ N Exxua ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}" current

9 May 2024

• 14:3514:35, 9 May 2024 diff hist +123‎ User:Rithish Nimmagadda ‎ →‎Education
• 14:3214:32, 9 May 2024 diff hist +11,409‎ Epcoritamab-bysp ‎No edit summary current
• 13:1413:14, 9 May 2024 diff hist +4‎ Epcoritamab-bysp ‎No edit summary
• 13:1013:10, 9 May 2024 diff hist +46‎ N Epcoritamab-bysp ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}"

8 May 2024

• 14:4414:44, 8 May 2024 diff hist +81‎ N Template:VSRN ‎ Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]" current
• 14:3014:30, 8 May 2024 diff hist +2‎ FRUZAQLA ‎No edit summary current Tag: Visual edit
• 14:2514:25, 8 May 2024 diff hist +35‎ FRUZAQLA ‎No edit summary
• 14:2114:21, 8 May 2024 diff hist −9‎ User:Rithish Nimmagadda ‎ →‎Your Name
• 14:2114:21, 8 May 2024 diff hist +9‎ User:Rithish Nimmagadda ‎ →‎Your Name
• 14:2014:20, 8 May 2024 diff hist +362‎ N User:Rithish Nimmagadda ‎ Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India"
• 14:1014:10, 8 May 2024 diff hist +9,092‎ N FRUZAQLA ‎ Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma..."
• 13:3213:32, 8 May 2024 diff hist +49‎ N Fruzaqla ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}" current